BioCardia, Inc.
BioCardia, Inc.
Your view on BCDAW
Overview
What the company does, where it operates, and who runs it.
About BioCardia, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Peter A. Altman
- Headquarters
- 320 Soquel Way, Sunnyvale, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Peter A. Altman
- Headquarters
- 320 Soquel Way, Sunnyvale, CA, US
BioCardia, Inc. is a regenerative medicine enterprise, currently in the clinical development phase, dedicated to devising cell-based and cell-derived treatments for cardiac and pulmonary ailments. Its primary therapeutic offering is CardiAMP, an autologous mononuclear cell therapy system designed to address heart failure and persistent myocardial ischemia. In parallel, the company is advancing allogeneic cell therapies for various heart and lung diseases, including an investigational platform utilizing culture-expanded bone marrow-derived mesenchymal cells, which is presently in Phase I/II trials for ischemic heart failure. Beyond its therapeutic pipeline, BioCardia provides the Helix biotherapeutic delivery system, engineered to precisely inject treatments into the heart muscle via an internal helical needle, alongside Morph deflectable guides and sheaths. The company's operations are headquartered in Sunnyvale, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for BioCardia, Inc., and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for BioCardia, Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for BioCardia, Inc.. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for BioCardia, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for BioCardia, Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
BioCardia, Inc. valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold BioCardia, Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by BioCardia, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming BioCardia, Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming BioCardia, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for BioCardia, Inc.. Press releases and market coverage, newest first.